Fate Therapeutics Inc (Nasdaq: FATE) muaj txiav txim siab txiav kev sib koom tes thiab kev xaiv pom zoo nrog Janssen Biotech Inc, ib tug Johnson & Johnson chav tsev (NYSE: JNJ), ntawm kev hloov kho cov nqe lus thiab cov xwm txheej.
Daim ntawv cog lus tau raug txiav lawm, thiab tag nrho cov kev sib koom tes yuav raug mob nyob rau hauv thawj peb lub hlis twg ntawm 2023.
"Peb poob siab tias peb tsis tuaj yeem ua raws li Janssen ntawm lawv qhov kev thov kom txuas ntxiv ntawm peb txoj kev koom tes," Fate CEO Scott Wolchko tau hais.
Lub tuam txhab tau txo nws cov naj npawb rau kwv yees li 220 tus neeg ua haujlwm. Nws yuav txiav tawm qee qhov ntawm nws cov kev pab cuam ntawm tes tua kab mob hauv cov mob myeloid leukemia, B-cell lymphoma, thiab cov qog nqaij hlav.
Fate Therapeutics xaus rau lub quarter thib plaub nrog kwv yees li $ 475 lab nyiaj ntsuab, cov nyiaj sib npaug, thiab cov nyiaj tau los. Raws li nws qhov tseem ceeb ntawm cov raj xa dej thiab cov nqi txo qis, lub tuam txhab cia siab tias yuav muaj nyiaj txiag khiav los ntawm 2025.
Lub pact tau pib kos npe rau hauv 2020, thiab Fate Therapeutics tau txais $ 100 lab nyiaj ntsuab thiab Tshuag thiab yuav luag $ 3 nphom hauv kev them nyiaj tseem ceeb.
Nqe Nqis: FATE shares poob 62.80% ntawm $ 4.10 ntawm daim tshev kawg rau hnub Friday.
Saib ntxiv ntawm Benzinga
Tsis txhob nco lub sijhawm ceeb toom ntawm koj cov khoom lag luam - koom Lub Npe Lub Npe Pro dawb! Sim cov cuab yeej uas yuav pab koj nqis peev smarter, sai dua, thiab zoo dua.
© 2023 Benzinga.com. Benzinga tsis muab lus qhia txog peev. Qoob loo.
Tau qhov twg los: https://finance.yahoo.com/news/fate-therapeutics-ends-collaboration-deal-152718765.html